Clinical trial
Phase I Trial of R115777 (NSC 702818) in Relapsed, Refractory or High Risk Myeloid Leukemia
NCT00101296 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase I Trial of R115777 (NSC 702818) in Relapsed, Refractory or High Risk Myeloid Leukemia
- Lead sponsor
- National Cancer Institute (NCI)
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- October 31, 2004
- Completion date
- Not reported
- Enrollment
- 30 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
acute myeloid leukemia with multilineage dysplasia following myelodysplastic syndrome, adult acute erythroid leukemia (m6), adult acute megakaryoblastic leukemia (m7), adult acute minimally differentiated myeloid leukemia (m0), adult acute monoblastic leukemia (m5a), adult acute monoblastic leukemia and acute monocytic leukemia (m5), adult acute monocytic leukemia (m5b), adult acute myeloblastic leukemia with maturation (m2), adult acute myeloblastic leukemia without maturation (m1), adult acute myeloid leukemia with 11q23 (mll) abnormalities, adult acute myeloid leukemia with del(5q), adult acute myeloid leukemia with inv(16)(p13;q22), adult acute myeloid leukemia with t(16;16)(p13;q22), adult acute myeloid leukemia with t(8;21)(q22;q22), adult acute myelomonocytic leukemia (m4), adult erythroleukemia (m6a), adult pure erythroid leukemia (m6b), recurrent adult acute myeloid leukemia, untreated adult acute myeloid leukemia